Skip to main content
. 2021 Feb 16;10(2):406. doi: 10.3390/cells10020406

Figure 1.

Figure 1

(a) Progression-free survival (PFS) of metastatic melanoma patients treated with ipilimumab (orange line) and PD1 inhibitors (blue line); (b) overall survival (OS) of the same population treated with the two class of check-point inhibitors.